Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


D&C RED Nos. 33 & 36

Executive Summary

NEW CLOSING DATE IS MARCH 3, 1987, FDA announced in a final rule published in the Sept. 4 Federal Register. The new provisional listing deadline extends the dyes' previous Sept. 3 closing date. The delay will provide for continued use of the additives "while expert scientific review continues. . .proponents of the use of these additives have an opportunity to submit additional evidence on their use, and FDA takes final action," FDA said. The rule also reaffirms the earlier proposed closing date extensions for seven other color additives. FDA extended the provisional listing of D&C Red Nos. 8, 9, 19, 37, D&C Orange No. 17 and FD&C Yellow No. 6 from Sept. 3 to June 6, 1986. The document also confirms that the new closing for D&C Red No. 3 is Sept. 3, 1986. FDA has requested a National Toxicology Program (NTP) peer review panel to recommend tests which may clarify findings of toxicity in studies on D&C Red No. 33. FDA has also asked NTP to consider what testing might shed light on the relationship between Reds 33 and 36 and D&C Red No. 9, a dye shown to be a splenic carcinogen in chronic animal studies. In recent comments to the agency, the Cosmetic, Toiletry and Fragrance Association offered to conduct quantitative risk assessments on Reds 33 and 36. The assn. is -also reviewing the feasibility of conducting "mechanism of action" studies to determine whether the dyes present a human health risk.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts